Positive and negative tissue-specific signaling by a nematode epidermal growth factor receptor by Lesa, Giovanni M. & Sternberg, Paul W.
Molecular Biology of the Cell
Vol. 8, 779-793, May 1997
Positive and Negative Tissue-specific Signaling by a
Nematode Epidermal Growth Factor Receptor
Giovanni M. Lesa and Paul W. Sternberg*
Howard Hughes Medical Institute and Division of Biology, 156-29, California Institute of
Technology, Pasadena, California 91125
Submitted December 11, 1996; Accepted February 3, 1997
Monitoring Editor: Judith Kimble
The major determinants of receptor tyrosine kinase (RTK) signaling specificity have been
proposed to be Src homology 2 (SH2) binding sites, phosphotyrosine-containing oli-
gopeptides in the cytoplasmic domain of the receptor. The Caenorhabditis elegans epider-
mal growth factor receptor homologue LET-23 has multiple functions during develop-
ment and has eight potential SH2-binding sites in a region carboxyl terminal to its kinase
domain. By analyzing transgenic nematodes for three distinct LET-23 functions, we show
that six of eight potential sites function in vivo and that they are required for most, but
not all, of LET-23 activity. A single site is necessary and sufficient to promote wild-type
fertility. Three other sites activate the RAS pathway and are involved only in viability
and vulval differentiation. A fifth site is promiscuous and can mediate all three LET-23
functions. An additional site mediates tissue-specific negative regulation. Putative SH2
binding sites are thus key effectors of both cell-specific and negative regulation in an
intact organism. We suggest two distinct mechanisms for tissue-specific RTK-mediated
signaling. A positive mechanism would promote RTK function through effectors present
only in certain cell types. A negative mechanism would inhibit RTK function through
tissue-specific negative regulators.
INTRODUCTION
Growth factor receptor tyrosine kinases (RTKs)l play a
critical role in intercellular communication in both
vertebrates and invertebrates, providing a link be-
tween extracellular signals and intracellular effectors.
Their activation influences a wide variety of cellular
responses including growth, metabolic homeostasis,
and survival (Carpenter and Wahl, 1990; Ullrich and
Schlessinger, 1990; Fantl et al., 1993; Dickson and
Hafen, 1994). Activation of RTKs upon ligand binding
results in oligomerization followed by autophosphor-
ylation or transphosphorylation on specific tyrosine
residues. This phosphorylation generates short sites
that have been shown to bind specific proteins via Src
homology 2 (SH2) domains. These proteins include
* Corresponding author.
Abbreviations used: EGFR, epidermal growth factor receptor;
GAP, GTPase-activating protein; PDGFR, platelet-derived
growth factor receptor; PLC-y, phospholipase C-y; RTK, recep-
tor tyrosine kinase; SH2, src homology 2; VPC, vulval precursor
cell.
the adapter GRB-2, which leads to RAS activation,
phospholipase C-y (PLC-,y), the tyrosine phosphatase
SHP-2 (Adachi et al., 1996), Ras GTPase-activating pro-
tein (GAP), and the regulatory subunit of phosphati-
dylinositol-30H-kinase (Ullrich and Schlessinger,
1990; Koch et al., 1991; Hernandez-Sotomayor and
Carpenter, 1992; Cohen et al., 1995; Heldin, 1995; Paw-
son, 1995). Interaction of RTKs with different sub-
strates is thought to result in activation of distinct
signaling pathways, thus producing different cellular
responses (Schlessinger and Ullrich, 1992).
Some growth factor RTKs have indeed been shown
to exert different activities through different SH2-bind-
ing sites. For example, the sites for PLC-,y and phos-
phatidylinositol-30H-kinase in the platelet-derived
growth factor receptor-,B (PDGFR-,3) promote chemo-
taxis, whereas the site for GAP mediates suppression
of migration (Kundra et al., 1994). In the fibroblast
growth factor receptor, the site binding PLC-,y is re-
quired for phosphatidylinositol turnover and Ca21
flux but not for mitogenesis (Mohammadi et al., 1992;
Peters et al., 1992). These studies suggest that the exact
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Figure 1. Structure of the LET-23 protein. All the LET-23 protein
(1323 amino acids) represented with the domains characteristic of
the EGFR family is shown in A. SP, signal peptide; Minor LBD,
minor ligand-binding domain; Cys I, cysteine-rich domain I; Major
LBD, major ligand-binding domain; Cys II, cysteine-rich domain II;
TM, transmembrane domain; Juxta, juxtamembrane domain; TK,
tyrosine kinase domain; C terminus, carboxyl-terminal tail. Part of
the TK domain and all of the carboxyl terminus are shown in B.
Vertical bars represent tyrosines. There are 10 tyrosines in the
carboxyl-terminal tail that define eight putative SH2- binding sites
(sites 1-8).
number and type of SH2-binding sites are the major
determinant of RTK signaling specificity. Nonetheless,
few biological assays on SH2-binding sites have been
carried out in intact organisms (for example, see
Maina et al., 1996) and little is known about the phys-
iological significance of SH2-binding sites in RTK sig-
naling (Cohen et al., 1995). Moreover, previous studies
in cell culture have not been able to assign functions to
the SH2 sites in epidermal growth factor receptor
(EGFR). For example, although specific EGFR sites
have been shown to bind specific substrates (Rotin et
Figure 2. Putative carboxyl-terminal SH2- binding sites in human
EGFR, Drosophila EGFR (DER), and LET-23.
al., 1992; Batzer et al., 1994; Batzer et al., 1995), elimi-
nation of one or some of these sites has never been
shown to result in specific functional alterations. In
contrast, even when all known SH2-binding sites are
eliminated by site directed mutagenesis and no asso-
ciation with known SH2 domain-containing proteins
can be detected, EGFR can still induce mitogenesis
and transformation (Decker, 1993; Li et al., 1994; Soler
et al., 1994).
LET-23 is a Caenorhabditis elegans member of the
EGFR family (Aroian et al., 1990): its extracellular por-
tion contains two ligand-binding domains alternated
with two cysteine-rich domains (Figure 1). The cyto-
plasmic region contains a tyrosine kinase domain and
a carboxyl-terminal tail. The tail contains tyrosines
that define eight putative SH2-binding sites (Figures 1
and 2) and is implicated in multiple functions (Aroian
and Sternberg, 1991): the portion containing sites 6, 7,
and 8 is important for viability and vulval differenti-
ation; the portion containing sites 2, 3, 4, and 5 medi-
ates fertility (Aroian et al., 1994). Mutations that elim-
inate LET-23 activity result in complete loss of these
functions (Aroian and Stemnberg, 1991). Complemen-
tation analysis indicated that a general decrease of
let-23 activity parallels with a decrease of all let-23-
mediated functions. In addition, it indicated that let-23
has qualitatively distinct functions (Aroian and Stemn-
berg, 1991; Aroian et al., 1994). These functions act to
control development in distinct tissues. Mosaic anal-
ysis indicated that let-23 acts cell-autonomously in the
vulval precursor cells (VPCs) to promote vulval dif-
ferentiation (Koga and Ohshima, 1995; Simske and
Kim, 1995) and suggested that the essential let-23 func-
tion is in cells other than the VPCs, possibly the ex-
cretory cell, a cell thought to control osmotic pressure
(Koga and Ohshima, 1995). Sterility produced by a
let-23 mutation arises from a defect in ovulation (Mc-
Carter and Schedl, personal communication) and
likely has a focus in the gonad.
LET-23 is likely to stimulate viability and vulval
differentiation via SEM-5 and LET-60. The vulvaless
(no vulva) and lethal phenotypes caused by sem-5 and
let-60 mutations are similar to those of let-23 muta-
tions. Also, genetic epistasis tests with gain-of-func-
tion alleles of let-23 and let-60 revealed that the three
genes act in a common pathway (Beitel et al., 1990;
Han et al., 1990; Clark et al., 1992; Katz et al., 1996).
To better understand how EGFR family tyrosine
kinases transduce their signals in vivo, we have tested
the significance of the LET-23 putative SH2-docking
sites (Figure 2) in such a manner that the intrinsic
regulatory complexity of the signal transduction path-
way is intact. We have altered the potential SH2-
binding sites of LET-23 in vitro and expressed the
resulting constructs in nematodes lacking LET-23 ac-
tivity. We have then used functional assays to detect
LET-23 activity in these transgenic nematodes and
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show that six of the eight LET-23 putative sites func-
tion in vivo. These sites are required to mediate most
but not all of LET-23 activity and they are not equiv-
alent. Some activate specific functions, one mediates
tissue-specific negative regulation, and one is promis-
cuous, promoting all LET-23 functions analyzed. To a
first approximation, viability and vulval induction are
stimulated by the same sites. Our data demonstrate
the physiological importance of SH2-binding sites in
an intact organism and suggest that at least two inde-
pendent mechanisms are used for RTK-mediated tis-
sue specificity.
MATERIALS AND METHODS
Strains and General Methods
The following mutations were used: LG II, let-23(nulls), mn23, syl5,
syi7, (Herman, 1978; Aroian and Steinberg, 1991; Aroian et al.,
1994), unc-4(eI20) (Brenner, 1974), mnC1[dpy-10(e128) unc-52(e444)]
(Herman, 1978); LG IV, dpy-20(el282) (Hosono et al., 1982); and LG
X, sem-5(n2019) (Clark et al., 1992). let-23(null) unc-4(e120)/mnC1;
dpy-20(e1282) and let-23(syl7) unc-4(e120)/mnC1; dpy-20(e1282); sem-
5(n2019) were constructed by following standard procedures.
Strains of the form let-23(syl7) unc-4(e120)/mnC1; dpy-20(el282);
sem-5(n2019); Ex were constructed by mating males from a let-
23(syl7) unc-4(e120)/mnC1; dpy-20(el282); Ex stable line with let-
23(syl7) unc-4(e120)/mnC1; dpy-20(el282); sem-5(n2019) hermaphro-
dites and then following standard procedures. Statistical tests of
significance were performed with Fisher's exact test with the InStat
2.00 program (GraphPad Software, San Diego, CA).
Assay for Modified let-23 Genes In Vitro
An intact let-23 genomic clone, pk7-13.8, rescues the defects asso-
ciated with loss-of-function alleles of let-23 (Aroian et al., 1990;
Aroian et al., 1994; Simske and Kim, 1995; Katz et al., 1996; Simske et
al., 1996; Figure 3A). One or more carboxyl-terminal tyrosines en-
coded by this rescuing clone were changed to phenylalanines by
site-directed mutagenesis to alter LET-23 putative SH2-binding sites
(Figure 2). Each construct was expressed in a strain of genotype
let-23(null) unc-4(e120)/mnC1 [dpy-10(e128) unc-52(e444)]; dpy-
20(el282) [in most cases strain PS1484, which has the syl7 allele of
let-23; for the let-23(null) used in each experiment, see text and
legends]. unc-4 is a recessive mutation tightly linked to let-23 that
renders the worms uncoordinated: Unc-4 animals are also homozy-
gous for let-23(null). mnC1[dpy-10(e128) unc-52(e444)] is a balancer
that provides a wild-type allele of let-23 and unc-4 and inhibits
recombination in the region (Herman, 1978). It is used because
let-23(null)/let-23(null) animals die as young larvae (therefore,
PS1484 does not segregate Unc-4 animals). mnCl /mnCl worms are
immobile, semisterile, and easily recognizable under the dissecting
microscope.
High copy number germline transformation was carried out ac-
cording to Mello et al. (1991). Young adult hermaphrodites were
placed live on pads of 5% Noble agar under an inverted differential
contrast-interference (Nomarski) microscope (Carl Zeiss, Ober-
kochen, Germany) and DNA was injected into the gonad with an
Eppendorf microinjector model 5242 (Eppendorf Geratebau
Netheler, Hamburg, Germany). Except where noted, a mixture of 50
ng/,ul let-23 DNA, 15 ng/,il pMH86 [dpy-20(+)] DNA (Han and
Stemnberg, 1990), and 110 ng/,ul pBluescript II carrier DNA was
injected into animals from PS1484 (P0). pMH86 rescues the Dpy
phenotype. We picked F1 non-Dpy non-Unc hermaphrodites, cor-
responding to animals expressing the injected DNA. Every F1 worm
able to propagate the transgene to the following generations defines
a stable line. We maintained balanced stable lines and from those
we analyzed non-Dpy Unc-4 worms for the ability of the mu-
tagenized let-23 gene to rescue three phenotypes in the hermaphro-
dite: vulval induction, viability, and fertility (the transformation
scheme is outlined in Figure 4). As a control we injected a construct
that provides a wild-type copy of let-23 and, therefore, is able to
completely rescue all three phenotypes considered (Figure 3A).
NGros213-13.3 was injected at 50 ng/,ul along with 50 ng/,ul pRF4
[a plasmid containing a dominant mutant gene of rol-6 (Mello et al.,
1991)] and 100 ng/,ul pBluescript II as carrier DNA.
Scoring Viability
When we inject let-23(+) DNA (Figure 3A), which completely res-
cues defects associated with the let-23(null) alleles, including lethal-
ity (Figure 5), along with pMH86 [dpy-20(+)] into a let-23(null)
unc-4(e120)/mnCl; dpy-20(el282) mother (see Figure 4), all progeny
expressing the transgene are non-Dpy; the number of non-Dpy Unc
animals [nDU, genotype let-23(null) unc-4(e120); dpy-20(el282); Ex-
(construct A, pMH86)] should be half the number of non-Dpy non-
Unc animals [nDnU, genotype let-23(null) unc-4(e120)/mnCl; dpy-
20(el282); Ex(construct A, pMH86)] (Figure 4; Ex indicates an
extrachromosomal array). If a construct only partially rescues le-
thality, then the number of nDU will be less than one-half of the
number of nDnU. In general, the percentage of viability = 2x.100/y,
where x is the number of nDU and y is the number of nDnU.
To test whether let-23 constructs can overcome the reduced via-
bility due to decreased SEM-5 activity, we constructed strains of the
form let-23(syl7) unc-4(e120)/mnCl; dpy-20(el282); sem-5(n2019); Ex.
Ex contains the extrachromosomal transgene of interest (A, F, or H)
plus dpy-20(+) DNA. We also determined the viability of an iso-
genic strain with no extrachromosomal transgene (62.7%, n = 523).
Since transgenic animals have copies of dpy-20(+) DNA, they are
non-Dpy whereas nontransgenic animals are Dpy. Dpy non-Unc
animals (DnU) and nDnU are heterozygous for let-23. Animals
homozygous for let-23(syl7) and carrying the transgene are nDU.
We determined the transmission frequency (TF) of the transgene in
the strains let-23(syl7) unc-4(e120)/mnCl; dpy-20(e1282); sem-5(+);
Ex. Since TF = nDnU/(nDnU + DnU), a viability increase in trans-
genic nDnU animals results in higher TF. By comparing the nDnU
observed with the nDnU expected in case of complete overcome of
sem-5(n2019) inviability or no overcome at all of sem-5(n2019) invi-
ability, we can infer whether the transgene activity is SEM-5 depen-
dent in a let-23(syl7)/let-23(+); sem-5(n2019) background. To deter-
mine whether viability increases from a let-23(syl7)/let-23(+); sem-
5(n2019) background to a let-23(syl7); sem-5(n2019) background, we
counted nDnU and nDU. If viability does not differ, then nDU/
nDnU = 1/2. If viability does differ, nDU/nDnU > 1/2. By com-
paring the number of nDU observed with the expected number in
case of a bypass of sem-5(n2019) inviability or no bypass of sem-
5(n2019) inviability, we infer whether the transgene requires SEM-5
for its activity.
Scoring Vulval Induction
In C. elegans six cells, the VPCs, have the potential to divide three
times and generate vulval cells (i.e., adopt vulval fates; Sulston and
Horvitz, 1977; Sulston and White, 1980; Stemnberg and Horvitz,
1986). In wild-type hermaphrodites, only three VPCs adopt vulval
fates (Figure 5C), and the other three VPCs divide once and fuse
with the epidermis.
Vulval induction was scored under Nomarski optics at the L3
molt when the VPCs' nuclei that will form the vulva are at the
four-cell stage and easily visible. Vulval induction is 100% when
three VPCs are induced. Non-Dpy Unc-4 hermaphrodites were
placed live on pads of 5% Noble agar (Sulston and Horvitz, 1977;
Sternberg and Horvitz, 1981) and observed with a Plan l0OX
objective, Nomarski differential interference-contrast optics for
their extent of vulval induction. Vulval differentiation = number
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Figure 3. Ability of LET-23 carboxyl-terminal tyrosines to mediate viability, vulval differentiation, and fertility. The let-23(null) allele used
to test all of the constructs in this figure is let-23(syl 7). Carboxyl-terminal sites 1, 2, 3, etc., indicate that tyrosine(s) at that putative SH2-binding
site has not been changed; a dash indicates that each tyrosine in the corresponding site has been substituted with phenylalanine. Unshaded
bars in the fertility column represent semifertile animals (see below). The percent on the right of each column represents the weighted average
of all stable lines analyzed per construct. The tyrosine is essential, when phosphorylated, for binding a given SH2 domain and its elimination
prevents binding (Kazlauskas et al., 1990; Margolis et al., 1990; Fantl et al., 1992). n indicates the number of animals scored. Analysis of
phenotypes and relative calculations are fully explained in MATERIALS AND METHODS and in Figure 5. Viability is the proportion of
surviving animals. Vulval differentiation is the number of VPCs generating vulval progeny compared with wild-type (always 3) and scored
with Nomarski optics. To score fertility, brood size per hermaphrodite was counted: 0-1 progeny, sterile; 2-10, semifertile; >10 fertile.
Typically, the number of progeny observed (including dead larvae) was 40-70 for egg-laying-defective worms and >150-200 for
Molecular Biology of the Cell
.v ,v
782
LJ
72
1.
-m
00f'tS;000:;t-:0.;f: ;,00.f XTi
Signaling by a Nematode EGF Receptor
of VPCs induced/3 (100% vulval differentiation = three VPCs
induced).
Scoring Fertility
let-23 sterility is different from that observed in animals defective in
let-60(ras) (Beitel et al., 1990; Han and Sternberg, 1990), mpk-1 /sur-I
(Lackner et al., 1994; Wu and Han, 1994), and mek-2 (Wu et al., 1995),
where sterility is caused by alterations in meiotic cell cycle progres-
sion within the germline (Church et al., 1995). L4 or young adult
hermaphrodites were placed one per plate and checked every day.
Each plate was followed for 3 to 5 d for the presence of larvae or
vulvaless worms (see Figure 5). All progeny were counted, includ-
ing dead larvae. Animals were classified as follows, depending on
the number of progeny (shown in parentheses): sterile (0-1), semi-
fertile (2-10), or fertile (>10).
Site-directed Mutagenesis
Site-directed mutagenesis was carried out in pk7-5.5, a HindIII
clone of let-23 that contains the last 3 kb of a 3' coding sequence
plus -2 kb of 3' untranslated sequence. We used the method of
Deng and Nickoloff (1992), which permits direct mutagenesis of
double-stranded circular DNA (Clontech, Palo Alto, CA). A se-
lection primer was synthesized, SKNot (5'-ACCGCGGTG-
GCTAGCGCTCTAGAAC-3') that changes the NotI restriction
site in pBluescript II to an NheI site. Eighteen mutagenic primers
were synthesized. One primer, pS97, (5'-TGATGGGGATAGCTT-
TGAAAATTTATTAT-3'), introduces a G to A mutation at the
end of intron 17. Another primer, pSTX, (5'-CGCCATTTGATG-
GCTATTACTCTGAAAATTTATTA-3'), introduces two stop-
codons so that the resulting LET-23 protein is predicted to be
truncated at amino acid 1268. Eight primers alter the putative
SH2-binding sites: DY-1 (site 1, 5'-CTTCCTTGATCAAAGAA-
CATCTGTGGATCGA-3'), DY-2 (site 2, 5'-AAAGGCTCCGTTTT-
GAACCTAGATGAGTTT-3'), DY-3 (site 3, 5'-GTGCGGTTGAC-
CCAACTAAAATGCAAAATAATT-3'), YLIP-1 (site 4, 5'-
TTTGGAATAAG- AAATGAATTATCTTCC-3'), YTAV-1 (site 5,
5'-GTAACAGCTGTAAACAAAACTGCTG-3'), YYNQ-2 (site 6,
5'-TTTGGTTGGTTGAAGAAATCGCCATTTG-3'), YYNE-2 (site
7, 5'-TGTGGTTCATTGAAAAATCCAGAGGAAG-3'), and
YENE-1 (site 8, 5'-TCTTCATTTTCAAATTGAACTGCTTC-3').
Eight primers restore the putative SH2-binding sites: DY-WI
(site 1, 5'-CTTCCTTGATCAAAGTACATCTGTGGATCGA-3'),
DY-W2 (site 2, 5'-AAAGGCTCCGTTTTGTACCTAGATGAGTT
T-3'), DY-W3 (site 3, 5'-GTGCGGTTGACCCATCTAAAATG-
CAAAATAATT-3'), LIP-W (site 4, 5'-TTTGGAATAAGATAT-
GAATTATCTTCC-3'), TAV-W (site 5, 5'-GTAACAGCTGTATA-
CAAAACTGCTG-3'), NQ-W (site 6, 5'-TTTGGTTGGTTGTAGT-
AATCGCCATTTG-3'), NE-W (site 7, 5'-TGTGGTTCATTGTA-
ATATCCAGAGGAAG-3'), and ENE-W (site 8, 5'-TCTTCATTT-
TCATATTGAACTGCTTC-3').
Figure 3 (cont). egg-laying-competent worms. Some dead larvae
could be missed because they degrade and are difficult to see.
Wild-type brood size is -300 but egg-laying-defective animals
have a maximum of 70 progeny. For a given construct and a given
function, data from multiple stable lines were not statistically dif-
ferent from each other (p > 0.05), with two exceptions: one of three
lines of construct G showed lower viability; one of two lines of
construct J showed less vulval induction. These differences could
arise from mosaicism and differential stability of the transgene
(Mello et al., 1991). The data presented are consistent with data from
transient (Fl)-transformed animals and with observation of addi-
tional transformed lines. Analysis of Fl-transformation tests a much
larger number of independent transformation events.
Inject
let-23(mut) and dpy-20(+) DNAs
let-23(null) unc-4 Y20
balancer 'dpy-20
| Select stable lines (non-Dpy)
A
let-23(null) unc-4 dpy20
B balancer 'dpy-20' [let-23(mut); dpy-20(+)]
I Select non-Dpy Unc-4 progeny
let-23(null) unc-4 4Y.ilet-3(n l) ;dp-20 [let-23(mut); dpy-20(+)]C let-23(null) unc-4 'dpy-20'
Score LET-23 functions
D Viability Vulva Fertility
Figure 4. Strategy used to analyze the effects of in vitro-modified
let-23 genes on viability, vulval induction, and fertility. Worms with
a let-23(null) and dpy-20(-) background (A) were injected with a
wild-type [let-23(+)] (control) or altered [Uet-23(mut)] let-23 clone
along with a marker DNA [dpy-20(+)]. Stable lines were selected
based on segregation of non-Dpy progeny (B). Progeny (C) were
used for analysis. Since let-23 is required for viability, all viable
non-Dpy Unc-4 progeny will carry the transgene (C). For every
let-23 clone, we analyzed the extent of rescue of each LET-23 func-
tion in multiple independent transgenic lines (D).
The mutated fragments were then excised with Sall and HindIll
and ligated with an -12-kb EcoRI-SalI genomic let-23 fragment and
with an -3-kb EcoRI-SalI pBluescript II fragment generating the
plasmids in Figure 3. The correctness of the constructs was verified
by sequencing the mutated region plus the surrounding 200-300 bp.
RESULTS
An In Vivo Genetic System for RTK Function
Studies in cultured cells have demonstrated that, after
ligand binding, RTKs become phosphorylated at spe-
cific tyrosines (Schlessinger and Ullrich, 1992). In the
same experimental conditions, when these tyrosines
are removed, alternative sites normally not used could
become phosphorylated (Walton et al., 1990; Hernan-
dez-Sotomayor and Carpenter, 1992). In addition, very
little is known about the actual phosphorylation sites
of RTKs in intact organisms. Herein, we analyze
LET-23 function in different tissues and, therefore,
would need to know the precise phosphorylation state
of LET-23 in all of these tissues. Because at present this
is technically impossible, we used a different approach
and studied the functional significance of all LET-23
potential SH2-binding sites.
Before starting a systematic analysis of carboxyl-
terminal tyrosines, we carried out a series of control
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Figure 5. Nomarski photomicrographs of three distinct phenotypes associated with loss of LET-23 function. Lethality (A and B); vulval
differentiation (C and D); fertility (E and F). Wild-type (A, C, and E). let-23(loss-of-function) phenotypes (B, D, and F). Wild-type LI larva (A).
Dead LI larva (B). Lineage of the three VPCs at the four-cell stage that will divide again and form the vulva in a wild-type L3 larva (C) is
shown. The vulva is necessary for copulation and egg laying. In C. elegans three of six VPCs divide three times and form a vulva; the other
three divide once and fuse with a syncytial epidermis (hyp7; Horvitz and Sternberg, 1991). The same VPCs shown in C have divided only
once in a vulvaless L4 larva (D). When all VPCs divide only once and fuse with hyp7, the vulva does not form (vulvaless animal). An adult
wild-type hermaphrodite is shown in E (arrows, eggs). An adult sterile hermaphrodite (no eggs) is shown in F. Bars, 100 ,um (A and B) and
20 ,um (C-F).
experiments. We injected a wild-type let-23 clone in
let-23(mn23) unc-4/mnC1; dpy-20 animals (mn23 is a
let-23 genetic null allele that changes C700 to W700) and
analyzed their progeny. Injection mixes containing 5
ng/,ul (F1 analysis, viability = 24%, n = 67) or 20
ng/,ul (F2 analysis, viability = 76%, n = 177) only
partially rescued the lethality associated with mn23/
mn23. We found that, in this functional assay, a wild-
type let-23 clone at 50 ng/,ul mimics wild-type chro-
mosomal gene activity and rescues the defects
associated with let-23(syl7), a genetic null allele (Fig-
ure 3A). syl7 is a splice donor mutation predicted to
truncate LET-23 in the extracellular domain (Aroian et
al., 1994). We and others had previously shown that
the same genomic clone does indeed rescue defects
associated with other let-23 null or reduction-of-func-
tion alleles (Aroian et al., 1990, 1994; Koga and Ohs-
hima, 1995; Simske and Kim, 1995; Katz et al., 1996;
Simske et al., 1996).
We next tested the extent to which a multicopy trans-
gene would reproduce a chromosomal mutation, choos-
ing a mutation that would be the most sensitive. sy97 is
a let-23 genomic mutation in a splice acceptor site at the
ultimate exon, predicted to truncate LET-23 at amino
acid 1267 and to add 23 new amino acids (Aroian et al.,
1993, 1994). As a result sy97 eliminates putative SH2
binding sites 6, 7, and 8. No animals homozygous for
sy97 develop a vulva, only 11% are viable, but 95% are
fertile. (Figure 6; Aroian and Steinberg, 1991). We cre-
ated mutant forms of let-23 that would mimic the sy97
mutation. First we generated pS97, a let-23 construct
carrying the same G to A splice acceptor mutation as
sy97. Although mRNA analysis has not shown any wild-
type transcripts in sy97 animals (Aroian et al., 1993), the
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possibility exists that splicing nonetheless occurs at low
frequency at the mutated 3' splice site (AA) as it does at
other let-23 introns (Aroian et al., 1993). For this reason,
we generated pSTX, a mutant let-23 clone predicted to
eliminate the last 55 amino acids of LET-23 by inserting
two consecutive stop codons. We injected pS97 at 20 and
50 ng/,ul and pSTX at 20, 50, or 185 ng/,ul and found
that rescue does not increase when the dose of the trans-
gene is varied ninefold (Table 1). These experiments
show that, in the range of doses used, the pS97 and pSTX
transgenes confer viability and fertility comparable to
the ones observed in the sy97 genomic mutation. There is
an increase in the extent of vulval differentiation, consis-
tent with previous observations that sy97, although con-
ferring very little vulval induction on its own, can confer
vulval induction in the absence of negative regulators
(Huang et al., 1994; Jongeward et al., 1995). Moreover,
these observations demonstrate that increasing the
amount of let-23 transgene does not increase the extent of
rescue, rendering unlikely the hypothesis that the differ-
ential rescue observed is solely due to different stability
of the LET-23 protein in different tissues. The decrease of
LET-23 function observed when we injected 185 ng/,l
pSTX (Table 1), may depend on the different let-23(null)
background used. Since mn23 is a point mutation pre-
dicted to generate a protein with an amino acid substi-
tution in the extracellular domain of LET-23, it could
allow some signaling to occur. We therefore used the
syl7 null allele of let-23 in the recipient strain for our
analysis.
NGros213-13.3 is a genomic clone generated during
the molecular cloning of let-23 (Aroian et al., 1990) and
is predicted to be translated into a chimera containing
the LET-23 protein up to amino acid 1212 (putative
SH2-binding sites 2-8 are eliminated) plus 48 new
amino acids translated from in-frame vector se-
quences (Aroian et al., 1994; Figure 6). The 48 new
1 234 5 6 7 8
l l li I I
3N### .Wild-type LET-23
co
1 234 5
"IfEBI LET-23(sy97)
I NNG 2.~13-13.3
O.-
Vulva' Fertility
100% (many) 100% (many)
0% (n=21) 95% (n=22)
92% (n=13) 0% (n=79)
Figure 6. Vulval differentiation and fertility functions conferred by
wild-type LET-23, LET-23(sy97), and NGros213-13.3. On the left the
carboxyl-terminal end of LET-23 is shown. let-23(sy97) is predicted
to truncate LET-23 at amino acid 1267. NGros213-13.3 is predicted
to truncate LET-23 at amino acid 1212. The area surrounded by a
dotted line represents new amino acids (see text). N represents a
new putative SH2-binding site (YYNS). 'The presence of a vulva
was determined under Nomarski optics. 2Data from Aroian and
Steinberg (1991).
amino acids contain a putative SH2-binding site,
YYNS (Songyang et al., 1993; van der Geer et al., 1996)
similar to the LET-23 putative binding sites 6, 7, and 8
(Figures 2 and 6). NGros213-13.3 expressed at high
copy number does not rescue sterility but does rescue
lethality and vulvaless phenotypes associated with the
let-23(null) allele mn23 (Figure 6; see also Aroian et al.,
1994). If the phenotypes observed depend on LET-23
stability and if fertility is the function most sensitive to
LET-23 activity, then since NGros213-13.3 confers vi-
ability and vulval differentiation, it should be able to
confer fertility as well. These findings, along with the
sy97 data, suggested that the fertility function resides
upstream of the sy97 mutation (Aroian et al., 1994) and
Table 1. Ability of pS97 and pSTX transgenes to mediate viability, vulval differentiation, and fertility at different doses
Dose No.
let-23 injected Viability Vulvaa Fertility stable
background Transgene (ng/,ul) (%) (%) (%) lines
mn23 or syi5 0 (0)b (0)b NA
mn23 pS97 20 14 (n = 169) 33 (n = 21) 100 (n = 21) 3
mn23 pS97 50 12 (n = 217) 51 (n = 45) 100 (n = 45) 2
mn23 pSTX 20 20 (n = 475) 32 (n = 91) 100 (n = 91) 7
mn23 pSTX 50 29 (n = 259) 30 (n = 71) 100 (n = 71) 4
syl5 pSTX 185 17(n = 47) 10 (n = 65) 95 (n = 65) 2
sy97 NA 11 (n = 389) 0 (n = 21) 95 (n = 22) NA
pS97 and pSTX at 20 ng/,ul and at 50 ng/,d were injected into let-23(mn23) unc-4(eI20)/mnCl; dpy-20(el282) animals. pSTX at 185 ng/,ud was
injected into let-23(syl5) unc-4(e120)/mnCl; dpy-20(el282) animals. let-23(syl5) is a genetic null mutation whose defect has been localized in
the extracellular domain of LET-23 (Aroian, 1992).
aAnimals that laid eggs.
blf they survived, based on complementation tests (Aroian and Sternberg, 1991).
NA, not applicable.
Vol. 8, May 1997 785
G.M. Lesa and P.W. Sternberg
Tyros.ine
Kinase \
domain \
1 '8YFDQ
2 1225YKTE
3 232YGST
4 -42YLIP
,/ 5 YTAV
o7 6C YYNQP-- SEM-5- &
fertility 7;YYNEr / rvulva
8 'YENEP/
Figure 7. Model of in vivo LET-23-mediated activity for viability,
vulval differentiation, and fertility. The eight putative SH2-binding
sites in the carboxyl terminus of LET-23 are shown. Sites 1 and 3
have a minor role. Site 4 promotes all three functions. Dotted lines
indicate incomplete activation. Site 5 is necessary and sufficient to
activate wild-type fertility. Sites 6, 7, and 8 are specific for viability
and vulval differentiation. Site 2 has a negative effect on viability
and vulval development but not on fertility. Single-letter amino acid
code is used. Numbers to the left of the Ys indicate the amino acid
number (Aroian et al., 1990). All sites are conserved in Caenorhabditis
vulgaris, except site 7 (YYNQP) and site 8 (YQNE; Sakai et al., 1996).
that it is not the most sensitive to LET-23 activity.
Moreover, they raised the possibility that the putative
SH2-binding site YYNS might be sufficient to confer
full viability and vulval activity. Therefore, by a sys-
tematic functional analysis of all of the carboxyl-ter-
minal LET-23 putative SH2-binding sites, we investi-
gated whether they play a role in mediating LET-23
functions.
For the experiments described below, we set up an
assay that makes use of the intact C. elegans (Figure 4).
We mutated copies of a genomic wild-type let-23 clone
(Figure 3A) and then expressed them in animals lack-
ing LET-23 activity. We then analyzed three pheno-
types associated with let-23 function (Figure 5). Since
the phosphotyrosines are essential for SH2 binding,
we systematically mutagenized in vitro codons speci-
fying all LET-23 carboxyl-terminal tyrosine residues
(Figures 2 and 7), substituting them with phenylala-
nine codons. The tyrosine to phenylalanine change is
expected to prevent SH2 binding (Kazlauskas et al.,
1990; Margolis et al., 1990; Fantl et al., 1992). As de-
scribed by Mello et al. (1991), we introduced the engi-
neered let-23 constructs into nematodes with a let-
23(null) background and assayed their activity by
scoring transgenic animals for viability, vulval differ-
entiation, and fertility (for more details, see Figure 4
and MATERIALS AND METHODS). Each construct
was injected at 50 ng/,ul, except where noted.
The Carboxyl-Terminal Tyrosines Mediate Most but
Not All of LET-23 Activity
To clarify the functional relationship between the ac-
tivity of LET-23 and the carboxyl-terminal tyrosines,
we analyzed a LET-23 protein in which all carboxyl-
terminal tyrosines were substituted with phenylala-
nine residues (Figure 3B). Association between this
mutated LET-23 protein and the effectors that nor-
mally bind LET-23 via carboxyl-terminal tyrosines
should be prevented.
By analyzing transgenic worms expressing this con-
struct, we found that most of LET-23 activity depends
on its putative SH2-binding sites (Figure 3B): viability,
vulval induction, and sterility are all severely im-
paired but not completely abolished. This result indi-
cates that these sites are required in vivo for most, but
not all, of LET-23-mediated function. Similar results
were obtained with a construct-bearing site 3 alone
(Figure 3E), suggesting that this site has little or no
role in LET-23-mediated activity. Addition of site 1
increases viability slightly but has no other effect (Fig-
ure 3C), implying that this site can play only a minor
role in mediating LET-23 function. We expect that site
3 and probably site 1 are not phosphorylated.
A Single Site Is Necessary and Sufficient to Confer
Wild-Type Fertility
Experiments with let-23(sy97) and NGros213-13.3 sug-
gested that the fertility function resides in the carbox-
yl-terminal portion of LET-23 containing sites 2, 3, 4,
and 5 (Figure 6; Aroian and Sternberg, 1991; Aroian et
al., 1994). Consistent with these findings, we observed
that none of the sites deleted by the let-23(sy97) mu-
tation is able to confer fertility (Figure 3, H-J). Under
these conditions only two LET-23 carboxyl-terminal
sites can mediate fertility: sites 4 and 5 (Figure 3, F and
G). A let-23 construct bearing only site 5 confers full
fertility with no apparent increase in viability and
vulval differentiation (Figure 3G). Removal of site 5
from an otherwise wild-type let-23 construct decreases
fertility to 15% (Figure 3Q). Site 4 alone is able to
confer 14% fertility (Figure 3F). Although removal of
site 4 has no significant effect on fertility (Figure 30),
removal of both sites 4 and 5 decreases fertility to
approximately 0% (Figure 3N). Thus, site 5 appears to
be the major mediator of fertility in the wild-type
LET-23 protein.
Three Sites Are Specific for Viability and Vulval
Differentiation
We tested the physiological significance of sites 6, 7,
and 8 and found that each individually is able to
mediate viability and vulval differentiation but not
fertility (Figure 3, H-J). For example, site 7 increases
viability to 76%, and vulval differentiation to 99% of
wild type. Sites 6, 7, and 8 match consensus binding
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sites for SEM-5 (YXNX; Songyang et al., 1993; Figures
2 and 7). SEM-5, which is required for viability and
vulval differentiation (Clark et al., 1992), is homolo-
gous to the adapter protein GRB-2 (Lowenstein et al.,
1992) and associates with activated human EGFR
(Stern et al., 1993). Interestingly, an interaction be-
tween the YYN motif (present in both sites 6 and 7)
and GRB-2 has been recently documented in vivo (van
der Geer et al., 1996). All of these findings, along with
the proposed role of SEM-5 as an adapter protein
acting in the RAS-dependent vulva and viability path-
ways in C. elegans (Clark et al., 1992; Katz et al., 1996),
suggest that SEM-5 might interact with LET-23
through one or all of sites 6, 7, and 8 and lead to RAS
activation.
A Single Site Mediates Negative Regulation
The presence of site 2 in the absence of other carboxyl-
terminal sites or in the presence of site 3 results in
complete inviability (Figure 3, D and K). This obser-
vation suggests that site 2 acts negatively on viability
in vivo because the presence of only site 2 leads to 0%
viability compared with 11% viability in the absence
of all carboxyl-terminal sites.
To clarify the negative effect of site 2, we generated
transgenic worms expressing either a construct bear-
ing only site 2 and site 4 or a construct bearing only
site 2 and site 6 (Figure 3, L and M). The presence of
site 2 significantly decreases both viability and vulval
differentiation conferred by site 4 and site 6 but does
not affect fertility (Figure 3, compare L and M with F
and H; for vulval differentiation, the proportion of
animals with less than three VPCs induced versus
animals with three VPCs induced was found to be
statistically significant, p < 0.016 in all cases). There-
fore, site 2 acts in a subset of tissues requiring LET-23
and inhibits viability and vulval differentiation, the
functions mediated by SEM-5 (Clark et al., 1992) and
RAS (Beitel et al., 1990; Han and Sternberg, 1990; Han
et al., 1990). Site 4 confers less viability and vulval
activity than site 6 (Figure 3, F and H) and it may be
more strongly down-regulated by site 2 (Figure 3, L
and M). Elimination of site 2 from an otherwise wild-
type receptor does not cause any detectable pheno-
type (Figure 3P).
By analogy to the human EGFR, LET-23 is likely to
act as a multimer. This hypothesis is supported by the
fact that certain let-23 mutations display intragenic
complementation (Aroian and Sternberg, 1991). Thus,
a site might work only in cis or might affect the sig-
naling ability of another polypeptide in the complex.
To test whether the negative effect of site 2 is main-
tained in trans, we constructed transgenic animals that
express both a construct bearing only site 2 (100 ng/
,lI) and a construct bearing only site 4 (20 ng/,ul). As
a control we constructed transgenic animals that ex-
press a construct with no carboxyl-terminal tyrosines
(100 ng/,ul) along with a construct bearing only site 4
(20 ng/,tl). The construct bearing only site 4 in com-
bination with the construct without carboxyl-terminal
tyrosines promoted 71% viability (Table 2), but in
combination with a construct bearing only site 2 pro-
moted only 31% viability (p = 0.0051). We interpret
this significant decrease in viability as reflecting the
action of site 2 in trans to site 4. Similarly, site 2 in cis
to site 4 injected at 50 ng/,ul decreased viability from
95% (Figure 3F) to 64% (Figure 3L; p = 0.0012).
One Site Is Promiscuous and Essential for Complete
Viability
Sites 5, 6, 7, and 8 specifically activate a subset of
LET-23 functions. By contrast, site 4 contributes, to
different extents, to all functions. In worms expressing
a construct bearing only site 4, viability and vulval
differentiation are virtually wild-type but fertility is
14% of wild-type (Figure 3F).
Site 4 is not required for fertility but is required
for wild-type levels of viability, in the presence of
site 2. Site 4 alone, site 6 alone, sites 7 and 8, or sites
6, 7, and 8 together are not able to overcome the
negative effect of site 2 and confer complete viability
(Figure 3, L-O). Removal of site 4 in the presence
site 2 and of all other sites mediating viability and
vulval differentiation, decreases survival from 99%
to 75% (Figure 3, N and Q).
let-23 Constructs Do Not Overcome the Reduced
Activity of SEM-5
LET-23 is very likely to stimulate viability and vulval
formation via SEM-5. Loss-of-function mutations of
let-23 and let-60 are lethal (Herman, 1978; Beitel et al.,
1990; Han and Sternberg, 1990; Han et al., 1990; Aroian
and Sternberg, 1991). Reduction-of-function mutations
of sem-5 are partially lethal (Clark et al., 1992). Once we
found that site 6 and site 4 could stimulate viability
and vulval formation, we sought to test whether they
do so via SEM-5. To do this we tested the alternative
hypothesis by asking whether constructs bearing only
either site 6 or site 4 can bypass the requirement for
SEM-5. For this test we used the strong reduction-of-
function sem-5(n2019) allele (Clark et al., 1992). If these
clones did overcome sem-5(n2019) inviability, we
would conclude that multiple copies of let-23 con-
structs allow wild-type signaling independently of
SEM-5 and thus our results are not physiological. If
they did not overcome sem-5(n2019) inviability, we
would conclude that an overexpressed let-23 construct
still requires SEM-5 to confer its activities.
Briefly, we calculated expected values of viability
based on transgene transmission (TF) and penetrance
of sem-5(n2019) for two hypotheses: that viability stim-
ulated by a let-23 transgene does or does not bypass a
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Table 2. Viability conferred by a construct bearing only site 4 coinjected with a construct bearing only site 2 or a construct bearing no putative
SH2-binding sites
No.
Constructs Viability stable
coinjected Carboxyl-terminal sites (%) p lines
B
and and 71 (n = 135) 2
F - - - 4 - - - -
0.0051
D 2 - - - - - -
and and 31 (n = 121) 2
F - - - 4 - - - -
Either constructs B and F or constructs D and F along with pMH86 and pBluescriptII were coinjected into let-23(null) unc-4(e20)/mnCl;
dpy-20(el282) hermaphrodites and viability was evaluated as described in MATERIALS AND METHODS. Amount of DNA injected:
constructs B and D, 100 ng/,ul; construct F, 20 ng/,l, pMH86, 15 ng/,l; pBluescriptll, 40 ng/,ul.
sem-5 mutant. For example, in the presence of wild-
type chromosomal let-23 (syl7/+), with a wild-type
let-23 transgene (Table 3A, construct A) we observed
286 Dpy non-Unc (DnU) animals (since they are Dpy,
they do not carry the transgene). From this value we
calculated the expected number of non-Dpy non-Unc
(nDnU) animals (since they are non-Dpy, they have
the transgene) if there is no bypass of sem-5(n2019) or
nDnU = DnU-(TF/1 - TF) = 286(38/62) = 175. If
there is bypass we would expect nDnU = DnU-(TF/1
-TF)/viability of sem-5(n2019) = 175/0.627 = 279. To
make the same test in the absence of chromosomal
let-23 (syl7/syl7), we counted the non-Dpy Unc
(nDU) segregants from the same parents. The unc-4
mutation is tightly linked to let-23 and, therefore, es-
sentially all Unc animals are also homozygous for
let-23(syl7). Since the nDU will be 1/2 the nDnU, we
normalized by a factor of 2. We observed 173 nDnU
and, therefore, expected 173/2 = 86 nDU animals.
Testing the difference between the observed and the
expected number in both experiments, we conclude
that the let-23 transgenes cannot overcome sem-
5(n2019) inviability in the presence of wild-type chro-
mosomal let-23 [let-23(syl7)/let-23(+)] (Table 3A) or in
the absence of wild-type chromosomal let-23 [let-
23(syl7)/let-23(syl7)I (Table 3B).
DISCUSSION
In this study, we have used an intact organism to
analyze the functional significance of eight putative
SH2-docking sites in a C. elegans EGFR tyrosine kinase
homologue, LET-23. Since we do not yet know the in
vivo autophosphorylation sites of LET-23 in the spe-
cific cells of interest, we have analyzed transgenic
constructs altered in all of their putative SH2-binding
sites. We have found that six of eight sites have a
physiological role. We have also demonstrated that
these putative SH2-binding sites are not equivalent in
vivo and can mediate either positive or negative tis-
sue-specific regulation. Our results suggest that RTK
tissue specificity in vivo is regulated by at least two
independent mechanisms. We propose that tissue-spe-
cific effectors and tissue-specific negative regulators
act together to allow RTK activity in some cell types
and not in others.
Since the transgenes are present in multiple copies,
one concern is that their overexpression leads to re-
sults that are difficult to interpret. Overexpression of
let-23 does not cause hyperactivation of the vulval
induction pathway (Aroian et al., 1994; Simske and
Kim, 1995; Katz et al., 1996; Simske et al., 1996). By
contrast, overexpression of LIN-3, the ligand for the
LET-23 receptor (Katz et al., 1995), or overexpression
of let-60(ras) (Han and Sternberg, 1990) does produce
hyper activation of the vulva pathway. Moreover, our
experiments with different doses of pS97 and pSTX,
transgenes that mimic the predicted effect of the chro-
mosomal tissue-specific let-23 mutation sy97, show
that both let-23 transgenes have a similar pattern of
activities as let-23(sy97) (Table 1). let-23(sy97) results in
no vulval differentiation but has vulval activity in the
absence of negative regulation (Huang et al., 1994;
Jongeward et al., 1995). The increased vulva activity of
the pS97 and pSTX transgenes compared with the sy97
chromosomal mutation suggests that the vulva is to
some extent sensitive to an increase of let-23 copy
number. Because of our control experiments and the
internal consistency of our results, we believe that our
transgene experiments reflect to a first approximation
the physiological roles of the carboxyl-terminal ty-
rosines of LET-23 and thus provide significant insights
on how a member of the EGFR family of RTKs signals
in an intact animal. We cannot rule out that some of
the effects observed in transgenic lines would not ap-
pear in the corresponding gene-replacement experi-
ments.
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Table 3. let-23 transgenes do not overcome reduced SEM-5 activity
A. let-23(syl7)/let-23(+) backgrounda
No. of No. of
nDnU nDnU
No. of expected expected No. of
TFlb" DnU with with nDnU
Construct Carboxyl-terminal sites (%) observed hyplc hyp2d observed phyple Phyp2f
A 1 2 3 4 5 6 7 8 38.0 286 175 279 173 0.9459 0.0002
(n = 166)
F - - - 4 - - - - 49.0 135 130 207 100 0.1513 <0.0001
(n = 104)
H - - - - - 6 44.8 356 289 461 285 0.9108 <0.0001
(n = 116)
B. let-23(syl7)/let-23(syl7) backgroundg
No. of No. of
nDu nDu
No. of expected expected No. of
nDnU with with nDU
Construct Carboxyl-terminal sites observed hyp3h hyp4i observed Phyp3k
A 1 2 3 4 5 6 7 8 173 87 138 86 1.0000 0.0076
F - - - 4 - - - - 70 35 56 14 0.0119 <0.0001
H - - - - - 6 - - 297 149 237 162 0.5757 0.0043
Viability conferred in a sem-5 reduction-of-function background [sem-5(n2019)] by let-23 constructs bearing all carboxyl-terminal sites or site
4 only or site 6 only. (A) Viability in a let-23(syl7)/let-23(+); sem-5(n2019) background. (B) Viability in a let-23(syl7)/let-23(syl7); sem-5(n2019)
background. We first determined both the lethality caused by sem-5(n2019) as well as the TF of each array. If a given transgene does not
overcome the reduced activity of sem-5(n2019) to mediate its effect on viability, the TF of the transgene should be the same in both sem-5(+)
and sem-5(n2019) backgrounds. Conversely, if a transgene at least partially overcomes sem-5(n2019) inviability, transgenic animals in a
sem-5(n2019) background should be more viable than nontransgenic siblings. Thus, the TF of such a transgene should be higher. We
performed similar analysis to test whether three let-23 transgenes could overcome the reduced SEM-5 activity in a let-23(syl7)/let-23(+)
background (A). Then we carried out the same analysis in a let-23(syl 7) background (Unc animals, B). Statistical analysis was used to compare
the number of animals observed with the number of animals expected in case of complete SEM-5 dependence of the transgene or in case of
complete SEM-5 independence of the transgene. The fact that with construct F we observed significantly less than expected viability in a
let-23(syl7) background (B) is consistent with our observation (Fig. 3F) that this construct has less activity than wild-type LET-23.
aThe genotype is let-23(syl7)/let-23(+); dpy-20(el282); sem-5(n2019); Ex.
bTransmission frequency of the transgene (TF) is the fraction of progeny that carries the transgene and equals nDnU/(nDnU + DnU), where
nDnU are non-Dpy non-Unc animals and DnU are Dpy non-Unc animals. Dpy animals have lost the transgene; non-Dpy animals carry the
transgene.
CnDnU expected if there is no SEM-5 bypass (hypothesis 1) = DnU [TF/(1 -TF)].
dnDnU expected if there is SEM-5 bypass (hypothesis 2) = DnU [TF/(1-TF)I/viability of sem-5(n2019) = DnU lTF/(1-TF)1/0.627.
ep obtained by comparing the number of nDnU expected if there is no SEM-5 bypass (hypothesis 1) with the nDnU observed.
fp obtained by comparing the number of nDnU expected if there is SEM-5 bypass (hypothesis 2) with the nDnU observed.
gThe genotype is let-23(syl7)/let-23(syl7); dpy-20(el282); sem-5(n2019); Ex.
hNumber of non-Dpy Unc animals (nDU) expected if there is no SEM-5 bypass (hypothesis 3). By Mendelian segregation nDU are expected
to be one-half of nDnU.
'Number of nDU expected if there is SEM-5 bypass (hypothesis 4) = (nDnU/2)/viability of sem-5(n2019) = (nDnU/2)/0.627.
ip obtained by comparing the number of nDU expected if there is no SEM-5 bypass (hypothesis 3) with the nDU observed.
"p obtained by comparing the number of nDU expected if there is SEM-5 bypass (hypothesis 4) with the nDU observed.
Most of LET-23 Activity Depends on Carboxyl-
Terminal Tyrosines
We have shown that a LET-23 construct with no car-
boxyl-terminal tyrosines has less than 10% of wild-
type LET-23 activity. Some of these tyrosines define
sites that, in other experimental systems, have been
shown to interact with SH2 domains (Songyang et al.,
1993). These findings, combined with the data pre-
sented herein, suggest that downstream targets of
LET-23 interact with its putative SH2-binding sites
and that the interaction is required for LET-23-medi-
ated functions. Since we do not have direct biochem-
ical evidence for phosphorylation or binding of pro-
teins, other models are possible. The residual activity
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observed when all sites are mutated may reflect the
existence of effectors activated independently of direct
SH2 association or the fact that tyrosines in other
domains of the receptor can also be used for signaling
(Decker, 1993; Soler et al., 1993; Gotoh et al., 1994; Li et
al., 1994).
Viability and Vulval Differentiation
LET-23 tyrosine sites 6, 7, and 8 specifically mediate
viability and vulval differentiation and match consen-
sus binding sites for SEM-5 (YXNX; Songyang et al.,
1993; Figures 2 and 7). Mutant animals with very low
SEM-5 activity show viability and vulval defects but
are not sterile (Clark et al., 1992), suggesting that
SEM-5 is not required for fertility. SEM-5 is structur-
ally and functionally homologous to the RAS activator
GRB-2 (Lowenstein et al., 1992; Egan et al., 1993) and
can associate with activated human EGFR (Stern et al.,
1993). Moreover, it has recently been shown that the
YYN motif when phosphorylated at both tyrosines has
a strong affinity for GRB-2 in vivo (van der Geer et al.,
1996). In addition, site 6 does not overcome the invi-
ability associated with a reduction of SEM-5 activity.
Therefore, it seems likely that SEM-5 binds to LET-23
through site 6, and probably through sites 7 and 8, and
leads to RAS activation.
Site 4 is different from sites 6, 7, and 8 in that it is
able to confer fertility as well as viability and vulval
differentiation. Site 4-mediated viability is SEM-5 de-
pendent, suggesting that site 4 also leads to RAS acti-
vation and might bind SEM-5. We cannot rule out the
possibility that site 4 can bind SEM-5 only in the
absence of sites 6, 7, and 8. Moreover, site 4 does not
match the consensus for SEM-5 binding and might
interact with another adapter to mediate its functions.
Fertility
Only two sites appear to mediate fertility: site 5 and
site 4. Since removal of site 4 has no significant effect
on fertility and since removal of both sites 4 and 5
results in almost complete sterility, we conclude that
site 4 is not required when site 5 is present but can
partially compensate for the absence of site 5. There-
fore, site 5 is necessary and sufficient to activate fer-
tility. Site 4 could confer some fertility by interacting
at low efficiency with the protein(s) that normally
binds to site 5.
Since sites 6, 7, and 8 appear to activate RAS to
mediate viability and vulval differentiation, our re-
sults suggest that the pathway branches at the level of
the receptor and that the fertility pathway activated by
LET-23 through site 5 employs a distinct set of effec-
tors (Figure 7; Jongeward et al., 1995). Indeed, genes
involved in LET-23-mediated fertility but not in via-
bility and vulval induction have been identified (Clan-
dinin and Sternberg, unpublished observation).
Since site 5 has the most specific effect, it is possible
that the fertility function is the most sensitive to a
reduction of let-23 activity. However, data from exten-
sive complementation analysis (Aroian and Sternberg,
1991) are not consistent with this possibility. Indeed,
the let-23(syl) mutation is the most specific, affecting
only vulva formation.
Negative Regulation
We have shown that LET-23 site 2 specifically inhibits
viability and vulval differentiation, two RAS-depen-
dent functions. There are a few other examples of
tyrosine sites mediating negative regulation in RTKs.
Valius et al. (1995) have shown that a GAP-binding site
in PDGFR-(3 down-regulates PLC-y-mediated activity.
Cleghon et al. (1996) have found that a tyrosine site in
the Drosophila PDGFR homologue Torso inhibits sig-
naling. Weidner et al. (1995) have demonstrated that
the Met receptor carries a tyrosine with a negative role
in its juxtamembrane domain.
The fact that viability and vulval differentiation (that
are approximately 100%) are decreased whereas fer-
tility (which is 14%) is not (Figure 3, compare F and H
with L and M) argues against a general destabilizing
effect of site 2 on the LET-23 protein. If this were the
case, we would expect a decrease in the fertility func-
tion as well. Moreover, site 2 can negatively act on site
4-mediated viability in trans as well as in cis (Table 2).
Thus, these results suggest that site 2 interacts with
effectors leading to activation of tissue-specific nega-
tive regulation.
Four sites (sites 4, 6, 7, and 8) are required to over-
come the negative effect of site 2 and confer wild-type
viability. This observation suggests that there is no
redundancy for the viability function and that sites 4,
6, 7, and 8 might all be used in vivo. For vulval
induction, instead, a subset of the sites 4, 6, 7, and 8
seems to be sufficient to confer full vulval induction,
suggesting that they are functionally redundant. How-
ever, this difference could of course be due to the
apparent sensitivity of vulval differentiation to over-
expression of let-23 constructs.
We have also found that elimination of site 2 does
not result in inappropriate RAS pathway activation.
Why does elimination of site 2 produce no detectable
phenotype? Partially redundant negative regulators of
LET-23 have been genetically characterized and inac-
tivation of at least two of them is required to generate
a visible phenotype (Ferguson and Horvitz, 1989; Lee
et al., 1994; Jongeward et al., 1995; Yoon et al., 1995).
Therefore, it is likely that there is a threshold of de-
tectability for loss of negative regulation of LET-23.
Site 2 could mediate the function of one such negative
regulator.
We have shown that specific sites can activate dif-
ferent pathways to produce distinct functions. We
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have also provided evidence of negative regulation
specific for two RAS-mediated functions. Our find-
ings, therefore, suggest that RTK tissue specificity is
regulated in at least two ways in vivo. First, specific
SH2-binding sites could activate effectors present only
in particular cell types. Second, tissue-specific nega-
tive regulators could be used to modulate RTK activity
in some tissues but not in others. A combination of
these mechanisms would allow fine control of tissue-
specific pathway activation.
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